

Article

In Silico Evaluation of Paxlovid's Pharmacometrics for SARS-CoV-2: A Multiscale Approach

Ferenc A. Bartha ^{1,*} , Nóra Juhász ^{1,*} , Sadegh Marzban ¹ , Renji Han ²  and Gergely Röst ¹ 

¹ Bolyai Institute, University of Szeged, H-6720 Szeged, Hungary; sadegh.marzban@math.u-szeged.hu (S.M.); rost@math.u-szeged.hu (G.R.)

² School of Sciences, Zhejiang University of Science and Technology, Hangzhou 310023, China; renjihhan@csu.edu.cn

* Correspondence: barfer@math.u-szeged.hu (F.A.B.); juhaszn@math.u-szeged.hu (N.J.)

Abstract: Paxlovid is a promising, orally bioavailable novel drug for SARS-CoV-2 with excellent safety profiles. Our main goal here is to explore the pharmacometric features of this new antiviral. To provide a detailed assessment of Paxlovid, we propose a hybrid multiscale mathematical approach. We demonstrate that the results of the present in silico evaluation match the clinical expectations remarkably well: on the one hand, our computations successfully replicate the outcome of an actual in vitro experiment; on the other hand, we verify both the sufficiency and the necessity of Paxlovid's two main components (nirmatrelvir and ritonavir) for a simplified in vivo case. Moreover, in the simulated context of our computational framework, we visualize the importance of early interventions and identify the time window where a unit-length delay causes the highest level of tissue damage. Finally, the results' sensitivity to the diffusion coefficient of the virus is explored in detail.

Keywords: multiscale mathematical modeling; spatio-temporal dynamics; agent-based model; SARS-CoV-2; Paxlovid; virus diffusion



Citation: Bartha, F.A.; Juhász, N.; Marzban, S.; Han, R.; Röst, G. In Silico Evaluation of Paxlovid's Pharmacometrics for SARS-CoV-2: A Multiscale Approach. *Viruses* **2022**, *14*, 1103. <https://doi.org/10.3390/v14051103>

Academic Editors: Amber M. Smith and Ruian Ke

Received: 22 April 2022

Accepted: 17 May 2022

Published: 20 May 2022

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

Even with extensive vaccination, COVID-19 will most probably not be eradicated from the human populations; thus, new options for therapy need to be explored. This paper concentrates on the mathematical evaluation, assessment, and computation-based simulation of a promising antiviral drug, Paxlovid [1], which is essentially nirmatrelvir co-packaged with ritonavir. Nirmatrelvir is a protease inhibitor that is active against M^{Pro}: inhibition of the SARS-CoV-2 main protease renders it incapable of processing polyprotein precursors, preventing virus production. Ritonavir is given as a pharmacokinetic enhancer: it slows down nirmatrelvir's metabolism, allowing a twice daily administration regimen. Paxlovid (also known as PF-07321332) is orally bioavailable, and it has excellent in vivo safety profiles [2–4].

Modeling has enhanced our understanding of the dynamics of viral spread, and it played an instrumental role in developing successful therapies for chronic viral infections such as HIV and HCV [5]. Mathematical models have proved to be indispensable tools in overcoming the challenges posed by the SARS-CoV-2 pandemic, too. In terms of investigating cellular-level antiviral dynamics, one of the most modern, state-of-the-art approaches consists of considering each component's physical dimension and capturing them within the framework of a spatial multiscale model accordingly. These systems incorporate size in a particular manner: rather than operating with a simple numerical value, what changes in these models—depending on the size of a given biological entity—are the mathematical tools themselves that are applied to grasp these variables on different scales.

More formally, building on our previous work [6], we define a hybrid mathematical model by merging (i) a partial differential equation representing local virus concentration, (ii) an agent-based model describing target cells in the lung and their three possible

states (uninfected, infected, and dead), and (iii) a partial differential equation representing nirmatrelvir concentration. Naturally, the respective parts are closely and meaningfully intertwined: each considerable interaction and feedback process connecting these separate biological participants is given formal definition and appears in the implementation. A detailed motivation, definition and construction of this model type and its various advantages are discussed in [6]—here, we limit ourselves to highlighting the role of including crucial spatial mechanisms: unlike other classical models such as the ODE (ordinary differential equations) approach, the present system is defined in both space and time, and consequently, it is able to capture highly significant—and in nature inherently spatial—physical phenomena such as virus diffusion.

Our goal here is to provide an assessment of Paxlovid based on mathematical simulations. We explore questions such as what happens if nirmatrelvir is taken without ritonavir, or how do expectations for treatment outcome change if tablets are taken with some delay. We emphasise that performing the analogous *in vivo* experiments on an actual person or animal would be either simply impossible or unethical; at the same time, the corresponding *in silico* experiment can be conducted in just a few minutes at an ideally low cost.

While various other software packages implement hybrid mathematical concepts [7,8], we highlight that our implementation of the proposed multiscale system modeling Paxlovid is based on an adaptation of the free and open source library, HAL (Hybrid Automata Library) [9].

2. Methods

2.1. The Hybrid PDE-ABM Model

As described in Section 1, the main multiscale framework is defined via forming meaningful bridges between two important and fundamentally different modeling techniques: continuous partial differential equations and discrete agent-based models.

In the following, let Ω denote the area we are considering. For an *in vivo* experiment, this would mean a small part of the lung tissue, while in the case of an *in vitro* experiment it would be the area of a single well in a laboratory plate. Section 2.1.2 introduces the discrete part of our hybrid model accounting for epithelial cells, whereas Sections 2.1.2 and 2.1.3 discuss the continuous component modeling the virus (V) and drug (N) concentration. The cornerstone observation motivating this separation is that viruses and drug molecules are several magnitudes smaller than epithelial cells [10]. Then, we present the parametrization of the model in Section 2.2. Finally, Section 2.3 contains details of the implementation.

2.1.1. Epithelial Cells

One of the most important modeling decisions in [6] was defining epithelial cells as discrete agents in an agent-based model (ABM). The diameter of epithelial cells is relatively significant [11,12] and consequently, in terms of mathematical conceptualization, it is natural to approach cells as separate entities and follow their respective states on an individual level.

The discrete state space of target cells is defined precisely as in [6]. For completeness, we recall some of the fundamental technical details; namely, we construct a two-dimensional ABM state space by introducing a lattice of $k_1 \times k_2$ agents representing epithelial cells ($k_1, k_2 \in \mathbb{N}$). Cells are identified by means of the corresponding agent's place in the grid, or formally, by the (i, j) indices, where $(i, j) \in \mathcal{J} = \{(i, j) | 1 \leq i \leq k_1, 1 \leq j \leq k_2\}$. Finally, by setting the $\Omega_{i,j}$ notation for the open set occupied by the (i, j) -th cell, we have $\bar{\Omega} = \bigcup_{(i,j) \in \mathcal{J}} \bar{\Omega}_{i,j}$.

Regarding cell states in the context of the ABM space, the main concept is rather straightforward: each agent has three potential states. The latter is formally captured by the state function $s_{i,j}(t)$ representing that in this modeling framework, an epithelial lung cell is considered to be either *uninfected*, *infected*, or *dead*:

$$s_{i,j}(t) = \begin{cases} T, & \text{if the } (i,j)\text{-th cell is alive and uninfected at time } t \\ I, & \text{if the } (i,j)\text{-th cell is infected at time } t \\ D, & \text{if the } (i,j)\text{-th cell is dead at time } t. \end{cases}$$

We note that the *uninfected*, *susceptible*, and *target (cell)* expressions are used interchangeably in the context of viral dynamics: they all refer to living cells that are susceptible to SARS-CoV-2 infection but are (for the time being) free from it.

Concerning state dynamics, the transition rules are set to mimic the biological phenomenon in question, the complete list is as follows:

- All living uninfected cells are susceptible target cells to virus infection;
- Since the time frame of infection is relatively short, cell birth and cell division are ignored;
- Infection is not reversible: an infected cell can not become a healthily functioning uninfected cell again;
- Viral infection itself is the only reason for cell death, i.e., death related to any other natural cause is not accounted for (considering the 17-month half-life of lung epithelial cells [13], natural apoptosis may be ignored over the course of a 5-day Paxlovid treatment);
- The *uninfected*→*infected* state change: a target cell may become infected depending on the local virus concentration at the given cell. Infection itself is randomized and it occurs with a probability of P_I (for more details, see [6]);
- The *infected*→*dead* state change: Analogously to infection, death is governed by a stochastic model with probability P_D .

2.1.2. Virus Concentration

As discussed, virus concentration $V(t, x, y)$ is described as a variable that is continuously changing in both space and time, and as such, it is formally described by means of a partial differential equation (PDE):

$$\begin{cases} \frac{\partial V(t,x,y)}{\partial t} = D_V \Delta V - \mu_V V + (1 - \eta_N(N)) \cdot \sum_{(i,j) \in \mathcal{J}} g_{i,j}(t, x, y), & t > 0, (x, y) \in \Omega, \\ \frac{\partial V(t,x,y)}{\partial \nu} = 0, & t > 0, (x, y) \in \partial\Omega, \end{cases} \quad (1)$$

where D_V stands for the virus diffusion coefficient, μ_V represents the viral clearance rate, N is the local concentration of nirmatrelvir (i.e., the active antiviral component of Paxlovid), η_N is the efficacy function of nirmatrelvir, while $g_{i,j}$ denotes the viral source term for the (i, j) -th infected cell.

Equation (1) accounts for the following modeling assumptions.

- Virus particles spread across the domain primarily via diffusion.
- A non-specific, non-adaptive, simplified immune system is assumed which clears virions with a constant rate.
- A local nirmatrelvir concentration of $N(t, x, y)$ reduces virus production from infected cells by a ratio of $\eta_N(N(t, x, y))$; for more details, see Section 2.1.3.
- Infected cells generate new virus particles in a process that is formally described by the $g_{i,j}$ source functions:

$$g_{i,j}(t, x, y) = \begin{cases} 0, & \text{if } s_{i,j}(t) = T \text{ and } (x, y) \in \Omega_{i,j}, \\ f_{i,j}(t, x, y), & \text{if } s_{i,j}(t) = I \text{ and } (x, y) \in \Omega_{i,j}, \\ 0, & \text{if } s_{i,j}(t) = D \text{ and } (x, y) \in \Omega_{i,j}, \\ 0 & \text{if } (x, y) \notin \Omega_{i,j}. \end{cases} \quad (2)$$

In general, any reasonable $f_{i,j}(t, x, y)$ function may be allowed in the above formula (for more details, see [6,14]). We adopted the standard simplification commonly used in

the field of viral dynamics: analogously to [15,16], a constant virus budding rate is assumed. In particular, we used the estimate $f_{i,j} = 3.72 \times 10^{-3}$ copies/(mL · minute · cell); see [17].

2.1.3. Drug Concentration

Paxlovid (also known as PF-07321332) is an orally administered SARS-CoV-2 main protease inhibitor [2–4]. It is essentially a combination of two different drugs: nirmatrelvir—capable of effectively blocking virus production in infected cells—acts as its main antiviral component, while ritonavir serves to slow down the metabolism of nirmatrelvir to maintain significantly higher concentrations of the participant responsible for M^{pro} -inhibition. We emphasize that nirmatrelvir and ritonavir are not only separate entities as acting components: the corresponding drugs themselves are packaged in individual, separate tablets—this means that the theoretical possibility to take, for example, nirmatrelvir only (without the beneficial effect of ritonavir) is readily available. The remaining part of the section is dedicated to formulate the above statements in the context of the mathematical framework.

Nirmatrelvir concentration is modeled as a continuous variable and is denoted by $N(t, x, y)$. We highlight that—both for simplicity and because of the apparent lack of clinical data—we do not explicitly introduce the analogous $R(t, x, y)$ function for ritonavir concentration. Instead, we focus only on two specific scenarios: ritonavir is either taken as instructed (i.e., 100 mg of ritonavir every 12 h), or it is not taken at all. Formally, we introduce the boolean r to mathematically grasp the above concept:

$$r = \begin{cases} \text{true,} & \text{if ritonavir is taken following official regimen,} \\ \text{false,} & \text{if ritonavir is not administered at all.} \end{cases}$$

Hence, this boolean is responsible for controlling N through the metabolism-related descriptors.

Two further anatomical details need to be taken into account before we can formulate the governing equations for drug concentration.

First, capillary density is very high in the lung. For example, in the case of rats, there are about 11 epithelial cells per a single alveolus [18]. Considering that there are approximately 40 capillary loops per alveolus [19], this gives circa 4 capillary loops per epithelial cell. Consequently, because of the abundant presence of neighboring capillaries for a single cell, it is natural to assume a completely homogeneous drug distribution in the alveolar epithelium. Therefore, we work with $N(t)$ instead of $N(t, x, y)$, and the equation describing nirmatrelvir concentration becomes an ODE instead of a PDE.

Second, in order to reproduce the characteristic local concentration curves observed in clinical data (we refer to Figure 2A in [20]), we apply a standard pharmacokinetic (PK) dual compartment approach—akin to that utilized in [21]—assessing antiviral therapy targeting SARS-CoV-2. The latter model consists of a central compartment (e.g., stomach) responsible for first-level drug metabolism and a peripheral one (for the purpose of this manuscript the lung) containing the target site of nirmatrelvir. Technically, we introduce an additional $c(t)$ function representing drug concentration at the central compartment—this is the amount of nirmatrelvir that is already present in the patient's system but is not yet locally available at the level of the lung's epithelial cells. In the context of the two-compartment model, $N(t)$ corresponds to the peripheral compartment's nirmatrelvir concentration. Similarly to the case of $N(t)$, an ODE is used to describe $c(t)$.

The complete system for nirmatrelvir concentration is then formally described by the following set of equations:

$$\begin{cases} \frac{dc(t)}{dt} = -\mu_c(r)c(t) + S(t, r), \\ \frac{dN(t)}{dt} = -\mu_N(r)N(t) + \mu_c(r)c(t), \end{cases} \quad (3)$$

where S represents the nirmatrelvir source function in the body, corresponding to a twice-daily administration regimen (the time unit being $\tau = 1$ min):

$$S(t, r) = \begin{cases} K(r), & \text{if } \text{mod}(t, 12 \cdot 60) = 0 \\ 0, & \text{otherwise.} \end{cases}$$

The choice of $K(r)$ is discussed in the following section.

We note that the above set of equations holds primarily for in vivo scenarios. In case of in vitro experiments, one might, for example, consider a simpler, constant presence of nirmatrelvir.

2.2. Parametrization

The configuration of the stochastic ABM state space and the PDE layer describing SARS-CoV-2 infection had been given in [6]. Here, we set the parameter values that are related to the (new) calibrated layer representing Paxlovid-based antiviral therapy.

- Drug removal rates: $\mu_c(r), \mu_N(r)$. As we do not have direct information on the μ_c, μ_N coefficients, we deduce them indirectly by using frequently measured nirmatrelvir blood concentration values communicated in [20]. Of course, this argument raises the question of whether it is reasonable to use blood concentration values to estimate local drug concentrations in the lung—the validity of this approach is reassured by the results of [22]. The $\mu_c(r)$ and $\mu_N(r)$ coefficients were set using Wolfram Mathematica [23]. We note that in the process, we also benefited from a priori information on ritonavir from [20,24]: we used that in non-ritonavir-boosted cases, the active component is apparently metabolized 3–4 times faster. The Wolfram Mathematica notebook is available in our public Github repository [25].
- Efficacy: η_N . In our model, η_N is defined by means of a Hill function—the parameters of the latter are set precisely to obtain an efficacy of 50% when the drug concentration takes the value of EC_{50} for nirmatrelvir w.r.t. SARS-CoV-2 (the latter parameter is approximately 62 nM according to [3]). Formally, η_N is defined as

$$\eta_N(N(t)) = \frac{1}{1 + \frac{EC_{50}}{N(t)}}. \quad (4)$$

For simplicity, we use the notation $N(t)$ for drug concentration whether it is understood in nanomolars or in nanogramms per milliliter. Our implementation internally takes care of conversions when necessary due to data arriving from different sources.

The most important parameter values are summarized in Table 1.

Table 1. Parameter configuration is primarily based upon best fit to actual data communicated in [20]. Previously existing parameters are defined in [6].

Symbol	Parameter	Unit	Ritonavir–Boosted	Value
$\mu_c(r)$	drug removal rate in the stomach	τ^{-1}	false	0.015
			true	0.005
$\mu_N(r)$	drug removal rate in the lung	τ^{-1}	false	0.013
			true	0.004
$K(r)$	drug source in the stomach	ng/mL/ τ	false	1800
			true	6800

τ : time unit.

2.3. Implementation

The present work is a direct continuation of [6], and hence, its technical foundations and principles remain unchanged. For the sake of compactness, we avoid repetitive details—here, we limit ourselves to summarizing the extended structure of our updated software with the help of the flowchart in Figure 1.




Figure 1. The program flow diagram of the PDE-ABM model’s implementation based on HAL [9].

The chart is divided into two main columns. On the left, we have the program flow itself from start to finish, while the three additional boxes on the right contain further details the respective functions. After setup and initialization, the execution is controlled by a time loop: nirmatrelvir concentration, virus concentration, and cell states are updated for each time step (in our case $\tau = 1$ min).

1. Nirmatrelvir concentration is calculated first (highlighted with a green frame): the most fundamental details of the process are given on the right-hand side, highlighted with an identical color. There is a clear distinction between *in vitro* and *in vivo* cases: while the first scenario is implemented assuming a constant drug concentration, the latter utilizes a two-compartment PK system.

2. Updating virus concentration values entails recalculating the current values considering both natural decay and inflow from infected cells taking virus diffusion into account.
3. After the new drug and virus concentration values have been obtained at each cell, we are ready to update the cell states, i.e., consider potential cell infection and cell death—the former is highlighted in purple, the latter in gray. The schematic details are shown on the right with corresponding colors; we emphasize that the respective stochastic cores of these processes are very similar to each other. In both cases, the algorithm calculates the probability of either infection or death.

Our numerical simulations are based on a free and open source java software package, HAL (Hybrid Automata Library) [9]; our source code is publicly accessible in the Github repository [25].

3. Results

3.1. Replication of In Vitro Pharmacometrics of Paxlovid

The initial step in identifying and testing clinically promising antiviral drugs consists in performing a great number of in vitro experiments evaluating their overall effects. We begin with this straightforward approach, too. In this first scenario, we simulate a series of experiments corresponding to in vitro cases with different nirmatrelvir concentrations—all these configurations are otherwise identical in every other aspect. We simulate the course of SARS-CoV-2 infection over the course of four days, and we compare our computer-generated predictions with real-life observations obtained by scientific experiments assessing nirmatrelvir. Specifically, we consider Figure 3D in [2]—here, the authors evaluate PF-07321332 inhibition for (among other viruses) SARS-CoV-2 in viral-induced CPE assays, and their results are given for a series of different drug concentration values.

Figure 2 demonstrates a notable resemblance to Figure 3D in [2]. Key features of inhibition efficacy match in a reassuring way: the characteristic shape itself of the calculated curve looks identical to its clinical counterpart, and the numbers connected to the main concentration window (approximately between 10 and 300 nM) corresponding to tangible increase are essentially the same, too.




Figure 2. A simulated series of in vitro experiments with increasing initial nirmatrelvir concentrations. Concentration levels are assumed to be constant throughout the entire course of each experiment. Every simulation follows the emerging infection dynamics for 4 days. SARS-CoV-2 infection and nirmatrelvir treatment are initialized simultaneously. Our computer-generated predictions correspond reassuringly to real-life scientific measurements assessing infection inhibition of PF-07321332; see Figure 3D in [2].

While there is a clear match between clinical data and our calculated results, we highlight that there is a natural limit to accuracy due to a simple lack of data. Both simulated and real-life outcomes naturally depend on key features such as the number of days the experiment went on for or the complete resolution of the state space (i.e., the total

number of cells). While the supplementary material of [2] suggests that the authors mostly considered time intervals corresponding to 3–5 days, several parameter values are either unknown by nature or have not been disclosed.

3.2. Exploring In Vivo Pharmacometrics of Paxlovid

In this section, we present and explain our most significant computational results representing simplified in vivo cases. We explore a series of scenarios with various configurations, one basic feature remains unchanged however in all of them: we assume that the most fundamental instructions given in Paxlovid’s documentation [3] are followed at least for its nirmatrelvir component. Technically, this means that once patients start taking Paxlovid, they steadily take at least nirmatrelvir for 5 days straight, 1 dose every 12 h. Since Paxlovid is essentially nirmatrelvir co-packaged with ritonavir, technically, it is possible that a patient—either consciously because of an existing drug allergy or simply because of forgetfulness—takes only nirmatrelvir without the added benefits of ritonavir. This degree of freedom is allowed and investigated throughout the simulations. Some other combinations and scenarios were excluded due to lack of data; again, others were omitted simply because of the limited scope of the article.

Remark 1. *The inherent, rather sharp distinction between the in vitro and in vivo clinical categories becomes notably smoother in the simulated context of our mathematical model. Figuratively speaking, we perform in vivo experiments “as if they were” in vitro in the sense that we have full control over (and full information on) which specific biological or anatomical processes are included and which ones are left out. Our framework is called hybrid because of the different mathematical theories it unites, but it proves to be hybrid in this point of view as well.*

3.2.1. In Silico Testing of Immediate Paxlovid-Based Intervention

We begin by simulating three basic scenarios and observing the respective outcomes. Figure 3 shows the course of SARS-CoV-2 infection assuming no antiviral intervention, Figure 4 follows a case where the patient takes nirmatrelvir only (i.e., the main acting component of Paxlovid, without the benefits of ritonavir), while Figure 5 represents the scenario where Paxlovid is taken exactly according to official instructions.




Figure 3. Simulated spatiotemporal solutions captured (a) 24 h, (b) 48 h, (c) 72 h, and (d) 96 h after SARS-CoV-2 infection. No antiviral intervention took place in this case. The cellular state spaces are depicted on the left in all four subfigures; uninfected, infected and dead cells are denoted by green, purple, and black squares, respectively. Virus concentration values are shown on the right. The color bar is understood in virions per unit space.




Figure 4. Simulated spatiotemporal solutions captured (a) 24 h, (b) 48 h, (c) 72 h, and (d) 96 h after SARS-CoV-2 infection and simultaneous treatment with nirmatrelvir. In this case, nirmatrelvir was given without ritonavir and intervention took place with no delay. The cellular state spaces are depicted on the left in all four subfigures; uninfected, infected and dead cells are denoted by green, purple, and black squares, respectively. Virus concentration values are shown on the right according to the scale in Figure 3.




Figure 5. Simulated spatiotemporal solutions captured (a) 24 h, (b) 48 h, (c) 72 h, and (d) 96 h after SARS-CoV-2 infection and simultaneous treatment with Paxlovid. In this case, ritonavir-boosted nirmatrelvir was given, i.e., official instructions regarding Paxlovid were followed. Intervention took place with no delay. The cellular state spaces are depicted on the left in all four subfigures; uninfected, infected and dead cells are denoted by green, purple, and black squares, respectively. Virus concentration values are shown on the right according to the scale in Figure 3.

For the latter two cases, we plot total virus concentration and nirmatrelvir concentrations both at the first level of metabolism in the body and locally at the epithelial lung cells; the results are shown in Figure 6.




Figure 6. Integrated virus concentration and nirmatrelvir concentration levels for two different scenarios representing nirmatrelvir-based intervention. Subfigure (a) shows the simulated outcome of applying nirmatrelvir without ritonavir, while subfigure (b) depicts the results of rigorous treatment with Paxlovid (ritonavir-boosted nirmatrelvir). SARS-CoV-2 virus concentrations are colored in red (shown dashed), nirmatrelvir concentration levels— $N(t)$ and $c(t)$ —are depicted in sea green and light purple, respectively.

In Figure 6, both the integrated virus and drug concentration values are noteworthy. Firstly, we highlight that nirmatrelvir concentration levels clearly correspond to Figure 2A in [20]—this means that our simulations (both in the ritonavir-boosted and in the nirmatrelvir-only case) are running with highly realistic nirmatrelvir concentration levels. Secondly, our computational results correspond to straightforward, basic expectations suggested by the packaging of Paxlovid. In more detail, on the one hand nirmatrelvir in itself seems to be insufficient to control the infection (which explains why Paxlovid does not simply consist of nirmatrelvir tablets), and on the other hand, ritonavir-boosted nirmatrelvir is apparently capable of stopping infection entirely (which is in accordance with the simple fact that Paxlovid is an authorized drug of great promise).

3.2.2. Evaluating the Effects of Treatment Delay

The previous section's premise was similar to a classical *in vitro* configuration—in this original default case, infection and treatment began simultaneously. In order to make our model more realistic, here, we introduce and explore a new degree of freedom: treatment delay.

We begin by exploring how simulated predictions seen in Figures 4–6 would change if Paxlovid tablets were given with a delay.

In particular, Figures 7 and 8 illustrate virus dynamical processes that are otherwise identical to the scenarios of Figures 4 and 5, respectively, except for a 36-h delay in initiating nirmatrelvir-based treatment (this also means that we follow these cases for an overall longer time period). The ritonavir-boosted scenario is particularly interesting. Although the first 36 h see uninhibited virus spread, Figure 8 confirms that Paxlovid can control infection relatively well even in this particular, less favorable scenario: after the first 2 days, there are almost no new cell infections at all, and the only detectable change between the last four subfigures is infected cells gradually turning dead.

Similarly to Figure 6, Figure 9 shows integrated virus concentration and nirmatrelvir concentration levels, but, naturally, considering a 36-h delay before Paxlovid is given.




Figure 7. Simulated spatiotemporal solutions captured (a) 24 h, (b) 48 h, (c) 72 h, (d) 96 h, (e) 120 h, and (f) 144 h after SARS-CoV-2 infection and delayed treatment with nirmatrelvir. In this case, nirmatrelvir was given without ritonavir and intervention took place after a 36-h delay. The cellular state spaces are depicted on the left in all four subfigures; uninfected, infected and dead cells are denoted by green, purple, and black squares, respectively. Virus concentration values are shown on the right according to the scale in Figure 3.




Figure 8. Simulated spatiotemporal solutions captured (a) 24 h, (b) 48 h, (c) 72 h, (d) 96 h, (e) 120 h, and (f) 144 h after SARS-CoV-2 infection and delayed treatment with Paxlovid. In this case, ritonavir-boosted nirmatrelvir was given, i.e., official instructions regarding Paxlovid were followed. Intervention took place after a 36-h delay. The cellular state spaces are depicted on the left in all four subfigures; uninfected, infected and dead cells are denoted by green, purple, and black squares, respectively. Virus concentration values are shown on the right according to the scale in Figure 3.




Figure 9. Integrated virus concentration and nirmatrelvir concentration levels for two different scenarios representing nirmatrelvir-based intervention. In both cases, tablets are given after a 36-h delay w.r.t infection initialization. Subfigure (a) shows the simulated outcome of applying nirmatrelvir without ritonavir, while subfigure (b) depicts the results of rigorous treatment with Paxlovid (ritonavir-boosted nirmatrelvir). SARS-CoV-2 virus concentrations are colored in red (shown dashed), nirmatrelvir concentration levels— $N(t)$ and $c(t)$ —are depicted in sea green and light purple, respectively.

Now, we are ready to move on to this section’s main purpose, namely, investigating outcomes and eventual averted tissue damage rates for a series of delay values with respect to the default (i.e., no delay) case. Note that with no particular immune response, total tissue damage (i.e., the ratio of cells that are either infected or already dead) after 5 days reaches 100%—this means that the ratio of eventually remaining susceptible target cells after Paxlovid treatment corresponds precisely to the damage that is averted because of Paxlovid.

Figure 10 illustrates the damaging effect of treatment delay from two different viewpoints.

The first one, Figure 10a, considers averted damage for a series of scenarios where each scenario assumes a 12-h additional delay compared to the previous one. We highlight the sharp fall in effectiveness after a delay of 1.5 days: lack of timely Paxlovid-based antiviral intervention proves to be the most costly at this exact time window. For clarity, we note that the expression *surviving cells* refers to the fraction of initially susceptible cells that has not become infected by the end of the observation period.

The main idea of the second approach (Figure 10b) is to redefine the quantity on the horizontal axis: here, instead of linearly increasing delay times, the x axis follows initial damage rates (i.e., the level of damage that has been done until the moment treatment with Paxlovid is started). In other words, the latter approach depicts the relation between initial damage and averted damage.




Figure 10. The damaging effect of treatment delay in two different approaches. Both subfigures illustrate the ratio of remaining uninfected target cells—the substantial difference between the two plots is the quantity measured on the horizontal axes. Subfigure (a) follows time, directly, on its x axes, while graph (b) depicts results w.r.t. initial damage rates. Results were calculated with the same fixed diffusion coefficient as used in [6], namely, $D_V = 0.2\sigma^2/\text{min}$.

Due to the lack of precise clinical data—and consequently, the relative uncertainty—regarding the exact diffusion coefficient value of SARS-CoV-2, we explore the respective sensitivity of the results shown in Figure 10b. Specifically, Figure 11 illustrates the corresponding results in a heatmap for different diffusion values. Compared to the default scenario assuming $D_V = 0.2$, the outcomes do not change substantially for even significantly higher D_V values; however, there is a clear pattern suggesting that infection outcomes are expected to be more favorable if the diffusion coefficient is several magnitudes lower.




Figure 11. Interplay between the virus diffusion coefficient (horizontal axis) and tissue damage at the initialization of Paxlovid treatment (vertical axis). The column corresponding to the particular (default) virus diffusion value of $D_V = 0.2\sigma^2/\text{min}$ (the one used in [6]) is highlighted with purple.

Finally, we visualize the potency of Paxlovid in Figure 12: in this graph, we principally approach damage rates as areas. While this image is similar to Figure 10b in that the horizontal axis corresponds to initial damage, Figure 12 is ultimately structured differently. It distinguishes three types of damages and represents them as two-dimensional volumes—namely, we consider initial damage, damage after treatment initialization, and averted damage.

Naturally, the area between the $x = y$ line—depicted in (dotted) red—and the horizontal axis corresponds to the level of tissue damage suffered until the moment of Paxlovid-based intervention, i.e., initial damage.

As our next step, we visualize the unavoidable damage that occurs after intervention begins: the (dotted) curve depicted with blue shows the further damage that takes place even after the patient starts taking Paxlovid. Evidently, the area between the red line and the blue curve is the visual representation of damage after treatment initialization. This rate of damage is especially high when soaring virus concentration values are combined with a significant fraction of susceptible target cells at the initialization time of Paxlovid treatment. The latter is explained simply by nirmatrelvir's mechanism of action: nirmatrelvir does effectively block virus production in infected cells, but it can not prevent target cells from getting infected, which is also apparent in the figure itself.

The third category, averted damage emerges in Figure 12 as the area between the blue curve and the horizontal line framing the graph from above (the latter naturally corresponds to the scenario where no medical intervention happens and full-scale damage takes place after 5 days). This shaded, light green area is the visual equivalent of the damage that is averted as a result of Paxlovid treatment, or in other words, the epithelial lung cells that are saved by this new M^{pro} inhibitor. Similarly to numerous other antiviral drugs (targeting a large variety of viruses), the principle of 'the sooner the better' proves to hold in this case, too: if intervention happens right at the beginning, almost the entire cell population can be saved by Paxlovid in case of a SARS-CoV-2 infection.




Figure 12. The visualization of averted damage as a result of Paxlovid treatment. The quantity on the horizontal axis (and the $x = y$ line itself) represents the level of cell culture damage suffered until Paxlovid treatment begins, while data points depicted in blue show the unavoidable further damage that occurs after therapy commences. The shaded areas are a precise visual representation of *initial damage* (red), *unavoidable post-intervention damage* (blue), and *averted damage* (green). Evidently, the light green area represents those healthily functioning epithelial lung cells that were ultimately saved by Paxlovid.

4. Discussion

Even with worldwide vaccination programs, SARS-CoV-2 and its newly emerging variants represent an unprecedented global challenge. Consequently, new alternative treatment options are still very much needed. This paper yields a mathematical, computation-based evaluation of one of the most promising SARS-CoV-2 inhibitors to date, Paxlovid. We implemented and carefully calibrated a multiscale mathematical framework to serve as a small *in silico* laboratory where the basic features of Paxlovid can be replicated, explained, and further investigated. Our calculations correspond to clinical expectations remarkably well: we successfully replicated the outcome of a real-life *in vitro* experiment in the simulated context of our model; moreover, both the sufficiency and the necessity of Paxlovid's two main components were verified by our computations for a simplified *in vivo* case. To further improve Paxlovid's assessment, we generated a heatmap investigating the results' sensitivity to the inherently vaguely specified virus diffusion coefficient.

The proposed hybrid model has its limitations. In its present form, the system operates on a simplistic two-dimensional grid, ignoring the complex 3D geometry of the lungs, which may introduce bias or delays in the predictions. The implementation of a biologically more realistic three-dimensional structure falls beyond the scope of this study and is subject of future research. The increase of dimension (and of lattice size) inevitably affects the computational load and, hence, requires additional, technical optimization of the code in order to achieve the desired performance. Similarly, the current assumption of a constant virus clearance rate is ignoring the intricacies of the immune system that is a major limitation when considering *in vivo* scenarios. While in real life, there is a significant virus release at burst, our model is averaging out the virus source over a time interval; hence, we work with constant virus production rates, similarly to [15,16]. Consequently, this limitation is responsible for a slight overestimation regarding advancement of virus release. We note that in the context of our model, it is straightforward to implement more sophisticated approaches as well (which would not be the case for example in an ODE-based system), and we also highlight that our source code includes a built-in option allowing to consider latency periods. However, that would require sufficiently detailed biological data for parametrization. Finally, we mention that our basic modeling approach to natural cellular life cycles, though being a simplification, is not expected to imply significant deviation from reality in the context of a 5-day long Paxlovid treatment: natural cell death is responsible only for circa 1% of cell population loss during this time frame according to the 17-month half-life of epithelial lung cells [13].

Despite the mathematical model's necessary simplifications and the short scope of this case study, we were able to visualize and verify the importance of early interventions; moreover, we identified the specific time window where delaying treatment initiation proves to be most costly. As for broader directions of future work, we highlight that such hybrid models and computational frameworks hold a great deal of promise with applications such as supporting clinical trials by means of *in silico* experiments. Computation-based evaluation and simulation of therapies not only can enhance optimization of treatments, but a further development of this technology could also serve to reduce the need for animal testing in the future.

Author Contributions: Conceptualization, G.R.; methodology, G.R.; software, S.M. and N.J.; validation, F.A.B., N.J., S.M., R.H., G.R.; formal analysis, F.A.B., N.J., S.M., R.H., G.R.; investigation, F.A.B., N.J., S.M., R.H., G.R.; resources, F.A.B., N.J., S.M., R.H., G.R.; data curation, F.A.B., N.J., S.M., R.H., G.R.; writing—original draft preparation, N.J.; writing—review and editing, F.A.B., G.R. and N.J.; visualization, F.A.B., N.J. and S.M.; supervision, G.R.; project administration, F.A.B., N.J., S.M., R.H., G.R.; funding acquisition, G.R. and F.A.B. All authors have read and agreed to the published version of the manuscript.

Funding: The authors were supported by TKP2021-NVA-09 and the National Research, Development and Innovation Fund of Hungary grants FK 138924 (FB), KKP 129877 (NJ,SM,RH), FK 124016 (GR). In addition, FB was also supported by ÚNKP-21-5 and the Bolyai Scholarship of the Hungarian

Academy of Sciences and RH was supported by the Youth Foundation of Zhejiang University of Science and Technology (Grant No. 2021QN001). Research was completed in the National Laboratory for Health Security, Hungary.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Pfizer. PAXLOVID™ (Nirmatrelvir Tablets; Ritonavir Tablets). Pfizer Medical Information. 2022. Available online: <https://www.pfizermedicalinformation.com/en-us/nirmatrelvir-tablets-ritonavir-tablets/clinical-pharmacology> (accessed on 21 April 2022).
2. Owen, D.R.; Allerton, C.M.; Anderson, A.S.; Aschenbrenner, L.; Avery, M.; Berritt, S.; Boras, B.; Cardin, R.D.; Carlo, A.; Coffman, K.J.; et al. An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19. *Science* **2021**, *374*, 1586–1593. [[CrossRef](#)] [[PubMed](#)]
3. FDA. Fact Sheet For Healthcare Providers: Emergency Use Authorization for Paxlovid™. United States Food and Drug Administration. 2022. Available online: <https://www.fda.gov/media/155050/download> (accessed on 21 April 2022).
4. EMA. Annex I—Conditions of Use, Conditions for Distribution and Patients Targeted and Conditions for Safety Monitoring Addressed to Member States—for Unauthorised Product—Paxlovid (PF-07321332 150 mg and ritonavir 100 mg)—Available for Use. European Medicines Agency. 2022. Available online: https://www.ema.europa.eu/en/documents/referral/paxlovid-pf-07321332-ritonavir-covid-19-article-53-procedure-conditions-use-conditions-distribution_en.pdf (accessed on 21 April 2022).
5. Perelson, A.S.; Ke, R. Mechanistic modeling of SARS-CoV-2 and other infectious diseases and the effects of therapeutics. *Clin. Pharmacol. Ther.* **2021**, *109*, 829–840. [[CrossRef](#)] [[PubMed](#)]
6. Marzban, S.; Han, R.; Juhász, N.; Röst, G. A hybrid PDE–ABM model for viral dynamics with application to SARS-CoV-2 and influenza. *R Soc. Open Sci.* **2021**, *8*, 210787. [[CrossRef](#)] [[PubMed](#)]
7. Gianlupi, J.F.; Mapder, T.; Segó, T.J.; Sluka, J.P.; Quinney, S.K.; Craig, M.; Stratford, R.E., Jr.; Glazier, J.A. Multiscale Model of Antiviral Timing, Potency, and Heterogeneity Effects on an Epithelial Tissue Patch Infected by SARS–CoV–2. *Viruses* **2022**, *14*, 605. [[CrossRef](#)] [[PubMed](#)]
8. Ghaffarizadeh, A.; Heiland, R.; Friedman, S.H.; Mumenthaler, S.M.; Macklin, P. PhysiCell: An open source physics-based cell simulator for 3-D multicellular systems. *PLoS Comput. Biol.* **2018**, *14*, e1005991. [[CrossRef](#)] [[PubMed](#)]
9. Bravo, R.R.; Baratchart, E.; West, J.; Schenck, R.O.; Miller, A.K.; Gallaher, J.; Gatenbee, C.D.; Basanta, D.; Robertson-Tessi, M.; Anderson, A.R. Hybrid Automata Library: A flexible platform for hybrid modeling with real-time visualization. *PLoS Comput. Biol.* **2020**, *16*, e1007635. [[CrossRef](#)] [[PubMed](#)]
10. Bar-On, Y.M.; Flamholz, A.; Phillips, R.; Milo, R. SARS-CoV-2 (COVID-19) by the numbers. *eLife* **2020**, *9*, e57309. [[CrossRef](#)] [[PubMed](#)]
11. Carcaterra, M.; Caruso, C. Alveolar epithelial cell type II as main target of SARS-CoV-2 virus and COVID-19 development via NF-Kb pathway deregulation: A physio-pathological theory. *Med. Hypotheses* **2021**, *146*, 110412. [[CrossRef](#)] [[PubMed](#)]
12. Mason, R.J. Biology of alveolar type II cells. *Respirology* **2006**, *11*, S12–S15. [[CrossRef](#)] [[PubMed](#)]
13. Rawlins, E.L.; Hogan, B.L.M. Ciliated epithelial cell lifespan in the mouse trachea and lung. *Am. J. Physiol. Lung Cell Mol. Physiol.* **2008**, *295*, L231–L234. [[CrossRef](#)] [[PubMed](#)]
14. Beauchemin, C.; Forrest, S.; Koster, F.T. Modeling Influenza Viral Dynamics in Tissue. In *Artificial Immune Systems; ICARIS, Lecture Notes in Computer Science; Bersini, H., Carneiro, J., Eds.; Springer: Berlin/Heidelberg, Germany, 2006; Volume 4163*.
15. Lord, J.S.; Bonsall, M.B. The evolutionary dynamics of viruses: Virion release strategies, time delays and fitness minima. *Virus Evol.* **2021**, *7*, veab039. [[CrossRef](#)] [[PubMed](#)]
16. Perelson, A.S. Modelling viral and immune system dynamics. *Nat. Rev. Immunol.* **2002**, *2*, 28–36. [[CrossRef](#)] [[PubMed](#)]
17. Hernandez-Vargas, E.A.; Velasco-Hernandez, J.X. In-host mathematical modelling of COVID-19 in humans. *Annu. Rev. Control* **2020**, *50*, 448–456. [[CrossRef](#)] [[PubMed](#)]
18. Laurent, G.J.; Shapiro, S.D. (Eds.) *Encyclopedia of Respiratory Medicine*, 1st ed.; Academic Press: Cambridge, MA, USA, 2006; Volume 3.
19. Willführ, A.; Brandenberger, C.; Piatkowski, T.; Grothausmann, R.; Nyengaard, J.R.; Ochs, M.; Mühlfeld, C. Estimation of the number of alveolar capillaries by the Euler number (Euler-Poincaré characteristic). *Am. J. Physiol. Lung Cell Mol. Physiol.* **2015**, *309*, L1286–L1293. [[CrossRef](#)] [[PubMed](#)]
20. Singh, R.S.; Toussi, S.S.; Hackman, F.; Chan, P.L.; Rao, R.; Allen, R.; Van Eyck, L.; Pawlak, S.; Kadar, E.P.; Clark, F.; et al. Innovative Randomized Phase 1 Study and Dosing Regimen Selection to Accelerate and Inform Pivotal COVID-19 Trial of Nirmatrelvir. *Clin. Pharmacol. Ther.* **2022**, cpt.2603. [[CrossRef](#)] [[PubMed](#)]
21. Goyal, A.; Cardozo-Ojeda, E.F.; Schiffer, J.T. Potency and timing of antiviral therapy as determinants of duration of SARS-CoV-2 shedding and intensity of inflammatory response. *Sci. Adv.* **2020**, *6*, eabc7112. [[CrossRef](#)] [[PubMed](#)]

22. Hu, W.J.; Chang, L.; Yang, Y.; Wang, X.; Xie, Y.C.; Shen, J.S.; Tan, B.; Liu, J. Pharmacokinetics and tissue distribution of remdesivir and its metabolites nucleotide monophosphate, nucleotide triphosphate, and nucleoside in mice. *Acta Pharmacol. Sin.* **2021**, *42*, 1195–1200. [[CrossRef](#)] [[PubMed](#)]
23. *Mathematica, Version 13.0.0*; Wolfram Research, Inc.: Champaign, IL, USA, 2021. Available online: <https://www.wolfram.com/mathematica> (accessed on 13 December 2021).
24. Olkkola, K.T.; Palkama, V.J.; Neuvonen, P.J. Ritonavir's role in reducing fentanyl clearance and prolonging its half-life. *Anesthesiology* **1999**, *91*, 681–685. [[CrossRef](#)] [[PubMed](#)]
25. Bartha, F.A.; Juhász, N.; Marzban, S.; Han, R.; Röst, G. Supplementary Codes for In Silico Evaluation of Paxlovid's Pharmacometrics for SARS-CoV-2: A Multiscale Approach. *GitHub* **2022**. Available online: <https://github.com/epidelay/paxlovid-x-sars-cov-2> (accessed on 21 April 2022).